Immutep Limited

NASDAQ:IMMP

Biotechnology

Healthcare
$0.37 +0.64%

+$0.00 today

Market cap
$55.01M
Beta
2.24
P/E (TTM)
-0.9
EPS (TTM)
-$0.06
52W Low $0.29High $3.53

Volume 3.10M

Average 13.46M

IMMP Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Immutep LimitedNASDAQ: IMMP

Net Income · Q2 FY2026 · quarter ended Dec 2025

Net income grows 96.8% year over year

Q2 FY2026 net income of A$44.04M (cash outflow) rose 96.8% year over year. Over 3 fiscal years it compounded at +24.0% a year.

Context

  • Net income amounted to 1218.0% of revenue in FY2025, up 106.2 pp from a year earlier.
  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -A$35.84M (-41.7%) for the fiscal year ending Jun 2026, a slowdown from the +43.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-A$44.04M— QoQ
Last fiscal yearJun 2025
-A$61.43M+43.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+96.8%——
1 year+43.8%-41.7%-85.5 pp
3-year CAGR+24.0%-27.4%-51.5 pp
5-year CAGR+0.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

AUD · from the cash flow

Latest · FY2025
(61.43M) AUD
Year-over-year change
-43.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How IMMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +43.8% is the 4th highest of 11, against a peer median of +25.1%.
  • Net income amounts to 1218.0% of revenue for IMMP, versus a peer median of 339.4%.
IMMP Competitors
Net Income for IMMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$80.71B USD+146477.0%+53.5%—
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$239.55M USD+441.4%—110.0%
CABACabaletta Bio, Inc.LTM Mar 2026$175.43M USD+38.4%+46.9%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$173.76M USD-31.1%-16.9%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$166.12M USD-770.3%+15.0%2895.1%
EDITEditas Medicine, Inc.LTM Mar 2026$108.95M USD-56.6%-10.1%281.6%
IMMPImmutep LimitedFY2025A$61.43M AUD+43.8%+24.0%1218.0%
CADLCandel Therapeutics, Inc.LTM Mar 2026$54.42M USD+37.5%+26.7%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$51.99M USD+12.6%+8.9%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€45.62M EUR+51.2%-14.2%339.4%
MREOMereo BioPharma Group plcLTM Mar 2026$35.71M USD-24.3%-0.3%7142.0%
Peer median (excluding IMMP) —+25.1%+8.9%339.4%

Competitors are the stored peer set for IMMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income(29.9M)(32.21M)(39.9M)(42.72M)(61.43M)
Depreciation & Amortization2.07M2.06M2.06M2.26M2.39M
Deferred Income Tax(7.29M)0(4.99M)00
Stock-Based Compensation1.7M1.49M2M1.8M1.16M
Change in Working Capital(1.99M)(1.56M)764.6K3.46M(8.54M)
Accounts Receivables(2.83M)(2.25M)(1.61M)601.77K(2.52M)
Inventory0813.92K000
Accounts Payables1.38M1.44M3.27M00
Other Working Capital(543.42K)(1.56M)(900.11K)2.86M(6.02M)
Other Non-Cash Items17.77M(8.04K)4.17M379.87K4.37M
Operating Cash Flow(17.64M)(30.23M)(35.88M)(34.82M)(62.05M)
Capital Expenditures(15.6K)(22.91K)(47K)(932.37K)(45.77K)
Acquisitions (Net)00000
Purchases of Investments000(20.09M)0
Sales of Investments00000
Other Investing Activities0016K(903.15K)(38.49M)
Investing Cash Flow(15.6K)(22.91K)(31K)(21.02M)(38.53M)
Debt Repayment(214.38K)(222.54K)(211.97K)(226.49K)(270.67K)
Common Stock Issued43.31M52.98M80.08M100.24M(164.79K)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.59M(2.43M)(3.83M)(4.83M)(254.46K)
Financing Cash Flow52.68M50.33M76.04M95.18M(525.12K)
Effect of Forex Changes(752.84K)(671.04K)3.3M(967.73K)6.73M
Net Change in Cash34.27M19.4M43.42M38.37M(94.38M)
Free Cash Flow(17.66M)(30.25M)(35.93M)(35.75M)(62.1M)

Immutep Limited

NASDAQ:IMMP

Intrinsic Alpha fair value

Locked

Current Price

$0.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.